Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)

NCT00984802 is registered in ClinicalTrials.gov with Ischemix, LLC as lead sponsor.

NCT NCT00984802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00984802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)
Lead sponsor
Ischemix, LLC
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
April 30, 2011
Enrollment
142 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

percutaneous coronary intervention, stable coronary artery disease